Striatal [11C]dihydrotetrabenazine and [11C] methylphenidate binding in Tourette syndrome

Neurology

Volumn 72, Issue 16, 2009, Pages 1390-1396

  Albin, R L ^a,b,c   Koeppe, R A ^c   Wernette, K ^c   Zhuang, W ^d   Nichols, T ^d,e   Kilbourn, M R ^c   Frey, K A ^c  

^a 5023 BSRB ^*  (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBON 11; CLONIDINE; DIHYDROTETRABENAZINE; DOPAMINE TRANSPORTER; GUANFACINE; METHYLPHENIDATE; SEROTONIN UPTAKE INHIBITOR; VESICULAR MONOAMINE TRANSPORTER 2; CARBON; DIAGNOSTIC AGENT; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; DRUG DERIVATIVE; SLC18A2 PROTEIN, HUMAN; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CAUDATE NUCLEUS; CELL MEMBRANE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; FEMALE; GENETIC HETEROGENEITY; GILLES DE LA TOURETTE SYNDROME; HUMAN; LIGAND BINDING; MALE; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PUTAMEN; ADOLESCENT; BINDING COMPETITION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SUBSTANTIA NIGRA; SYNAPTOSOME;

ADOLESCENT; ADULT; BINDING, COMPETITIVE; CARBON RADIOISOTOPES; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PRESYNAPTIC TERMINALS; SUBSTANTIA NIGRA; TETRABENAZINE; TOURETTE SYNDROME; VESICULAR MONOAMINE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 67449149886     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a187dd     Document Type: Article

References (40)

1. Albin RL, Mink JW. Recent advances in Tourette syndrome research. Trends Neurosci 2006;29:175-182.
2. Leckman JF. Tourette's syndrome. Lancet 2002;360:1577-1586.
3. Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain 2000;123:425-462.
4. Walkup J, LaBuda MC, Singer HS, Brown J, Riddle MA, Hurko O. Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet 1996;59:684-693.
5. Tourette Syndrome Association International Consortium for Genetics. Genome scan for Tourette disorder in affected-sibling-pair and multigenerational families. Am J Hum Genet 2007;80:265-272.
6. Swerdlow NR, Young AB. Neuropathology in Tourette syndrome: an update. Adv Neurol 2001;85:151-161.
7. Kalanithi PSA, Zheng W, Kataoka Y, et al. Altered parvalbumin-poskive neuron distribution in basal ganglia of individuals with Tourette syndrome. PNAS 2005;102:13307-13312.
8. Gerard E, Peterson BF. Developmental processes and brain imaging studies in Tourette syndrome. J Psychosom Res 2003;55:13-22.
9. Albin RL, Frey KA. Neuroimaging of Tourette syndrome. J Child Neurol 2006;21:672-677.
10. Meyer P, Bohnen NI, Minoshima S, et al. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome. Neurology 1999;53:371-374.
11. Albin RL, Koeppe RA, Bohnen NI, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 2003;61:310-315.
12. Baron JC, Martinot JL, Cambon H, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 1989;99:463-472.
13. Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008; 23:401-404.
14. Goetz CG, Pappert EJ, Louis ED, Raman R, Leurgans S. Advantages of a modified scoring method for the Rush Video-Based Tic Rating Scale. Mov Disord 1999;14:502-506.
15. Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 1997;17:919-931.
16. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihy-drotetrabenazine. J Cereb Blood Flow Metab 1999; 19: 1376-1384.
17. Minoshima S, Koeppe RA, Fessler JA, et al. Integrated and automated data analysis method for neuronal activation studies using O15 water PET. In: Uemura K, Lassen NA, Jones T, Kanno I, eds. Quantification of Brain Function: Tracer Kinetics and Image Analysis in Brain PET, International Congress Series 1030. Tokyo; Excerpta Medica: 1993;409-418.
18. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:1528-1537.
19. Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. New York: Thieme; 1988.
20. Genovese CR, Lazar N, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neurolmage 2002;15:870-878.
21. Malison RT, McDougle CJ, van Dyck CH, et al. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995;152:1359-1361.
22. Heinz A, Knable MB, Wolf SS, et al. Tourette's syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity. Neurology 1998;51:1069-1074.
23. Muller-Vahl KR, Berding G, Brucke T, et al. Dopamine transporter binding in Gilles de la Tourette syndrome. J Neurol 2000;247:514-520.
24. Stamenkovic M, Schindler SD, Asenbaum S, et al. No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette's disorder patients: a [(123)I]-beta-CIT SPECT-study. Eur Neuropsychopharmacol 2001;11:69-74.
25. Serra-Mestres J, Ring HA, Costa DC, et al. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Acta Psychiatr Scand 2004; 109:140-146.
26. Cheon KA, Ryu YH, Namkoong K, Kim CH, Kim JJ, Lee JD. Dopamine transporter density of the basal ganglia assessed with [123I] IPT SPECT in drug-naive children with Tourette's disorder. Psychiatry Res 2004;130:85-95.
27. Yeh CB, Lee CH, Chou YH, Chang CJ, Ma KH, Huang WS. Evaluating dopamine transporter activity with 99mTc-TRODAT-1 SPECT in drug-naive Tourette's adults. Nucl Med Commun 2006;27:779-784.
28. Ernst M, Zametkin AJ, Jons PH, Matochik JA, Pascual-vaca D, Cohen RM. High presynaptic dopaminergic activity in children with Tourette's disorder. J Am Acad Child Adolesc Psychiatry 1988;38:86-94.
29. Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, Kish SJ. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 2003;87:574-585.
30. Robertson MM, Althoff RR, Hafez A, Pauls DL. Principal components analysis of a large cohort with Tourette syndrome. Br J Psychiatry 2008;193:31-36.
31. Singer HS, Szymanski S, Giuliano J, et al. Elevated intra-synaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 2002;159:1329-1336.
32. Wong DF, Brasic J, Singer HS, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008;33:1239-1251.
33. Peterson BS, Staib L, Scahill L, et al. Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry 2001;58:427-440.
34. Bloch MH, Leckman JF, Zhu H, Peterson BH. Caudate volumes in childhood predict symptom severity in adults with Tourette syndrome. Neurology 2005;65:1253-1258.
35. Garraux G, Goldfine A, Bohlhalter S, Lerner A, Hanakawa T, Hallett M. Increased midbrain gray matter in Tourette's syndrome. Ann Neurol 2006;59:381-385.
36. Ludolph AG, Juengling FD, Libal G, Ludolph AC, Fegert JM, Kassubek J. Grey-matter abnormalities in boys with Tourette syndrome: magnetic resonance imaging study using optimized voxel-based morphometry. Br J Psychiatry 2006;188:484-485.
37. Wang L, Lee DY, Bailey E, et al. Validity of large-deformation high dimensional brain mapping of the basal ganglia in adults with Tourette syndrome. Psychiatr Res 2007;154:181-190.
38. Sowell ER, Kan E, Yoshii Y, et al. Thinning of sensorimotor cortices in children with Tourette syndrome. Nat Neu-rosci 2008;11:637-639.
39. Behen M, Chugani HT, Juhasz J, et al. Abnormal brain tryptophan metabolism and clinical correlates in Tourette syndrome. Mov Disord 2007;22:2256-2262.
40. Peterson BS, Choi HA, Hao X, et al. Morphologic features of the amygdala and hippocampus in children and adults with Tourette syndrome. Arch Gen Psychiatry 2007;64: 1281-1291.